---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-044325"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-04-05T23:59:59+00:00"
generated_at: "2026-06-04T01:56:00.601905+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics reports FY2023 operating loss of $19.4M; cash $2.8M at year-end

## Summary
- Cash $2.8M as of Dec 31, 2023; net $6.2M raised in Jan 2024; funding expected into late Q3/Q4 2024.
- R&D expenses $12.3M (up from $10.2M in 2022); G&A $7.2M (down from $8.4M); operating loss $19.4M.
- CEO Michael Dudley resigned; CFO Tom Fitzgerald named interim CEO; Philippe Calais appointed Executive Chairman.
- Phase 0 trial of TTX-MC138 completed; preliminary results suggest delivery to metastatic lesions in breast cancer patient.
- Phase 1 trial of TTX-MC138 planned mid-2024 subject to FDA authorization and IRB approvals.

## SEC filing metadata
- accession: 0001104659-24-044325
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-04-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924044325/0001104659-24-044325-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924044325/tm2411028d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-044325
- JSON: https://secwatch.observer/filing/0001104659-24-044325.json
- Plain text: https://secwatch.observer/filing/0001104659-24-044325.txt

## Key facts
- Earnings Releases
  Transcode Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.
  - Period: the fiscal year ended December 31, 2023
  - Result: reported results
  source text: On April 3, 2024, TransCode Therapeutics, Inc. issued a press release announcing its financial results and other business highlights for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465924044325/0001104659-24-044325-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.